Mef2C is a lineage-restricted target of Scl/Tall and regulates megakaryopoiesis and B-cell homeostasisGEKAS, Christos; RHODES, Katrin E; ARMSTRONG, Scott et al.Blood. 2009, Vol 113, Num 15, pp 3461-3471, issn 0006-4971, 11 p.Article

Molecular determinants of cetuximab efficacyVALLBÖHMER, Daniel; WU ZHANG; GROSHEN, Susan et al.Journal of clinical oncology. 2005, Vol 23, Num 15, pp 3536-3544, issn 0732-183X, 9 p.Article

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and BevacizumabSCHULTHEIS, Anne M; LURJE, Georg; HIRTE, Hal et al.Clinical cancer research (Print). 2008, Vol 14, Num 22, pp 7554-7563, issn 1078-0432, 10 p.Article

Molecular determinants of irinotecan efficacyVALLBÖHMER, Daniel; IQBAL, Syma; LENZ, Heinz-Josef et al.International journal of cancer. 2006, Vol 119, Num 10, pp 2435-2442, issn 0020-7136, 8 p.Article